PMV Pharmaceuticals Inc
NASDAQ:PMVP
Intrinsic Value
PMV Pharmaceuticals, Inc. engages in the development of p53 targeted small molecule drugs for the treatment of cancer. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of PMVP.
PMV Pharmaceuticals Inc's market capitalization is 92.9m USD.
PMVP stock price is 1.805 USD.
PMVP.
PMVP. Open DCF Valuation
PMVP. Open Relative Valuation
PMVP has upside potential of 394% compared to the average analyst price target.
Open Wall St Estimates
PMVP has negative Free Cash Flow for the last twelve months.
PMVP has negative Operating Income for the last twelve months.
PMVP has negative Net Income for the last twelve months.
PMVP's ROE (Return on Equity) has significantly decreased in the last 3 years from -11% to -29%, and is approaching profitability.
PMVP's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -180% to -222%, and is approaching profitability.
PMVP's ROE (Return on Equity) for the past 12 months is negative and is equal to -29%.
PMVP's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -222%.
PMVP's Altman Z-Score is very low and is equal to 0.81.
PMVP has negative three-year average ROE (Return on Equity): -22%. The company is not efficient at transforming stockholders' equity into net income.
PMVP has negative three-year average ROIC (Return on Invested Capital): -345%. The company is not efficient at using invested capital to generate operating income.
PMVP's short-term assets (207m USD) exceed its short-term liabilties (14m USD).
PMVP's long-term assets (252m USD) exceed its long-term liabilties (26m USD).
PMVP's D/E (Debt to Equity) is very low and is equal to 0.
Fundamental Analysis
PMV Pharmaceuticals Inc
Balance Sheet Decomposition
PMV Pharmaceuticals Inc
| Current Assets | 207.4m |
| Cash & Short-Term Investments | 203.1m |
| Other Current Assets | 4.4m |
| Non-Current Assets | 44.7m |
| Long-Term Investments | 25.5m |
| PP&E | 19m |
| Other Non-Current Assets | 190k |
| Current Liabilities | 14m |
| Accounts Payable | 3.2m |
| Accrued Liabilities | 10.8m |
| Non-Current Liabilities | 12.4m |
| Other Non-Current Liabilities | 12.4m |
Earnings Waterfall
PMV Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-80.1m
USD
|
|
Operating Income
|
-80.1m
USD
|
|
Other Expenses
|
11.2m
USD
|
|
Net Income
|
-69m
USD
|
Free Cash Flow Analysis
PMV Pharmaceuticals Inc
What is Free Cash Flow?
PMVP Profitability Score
Profitability Due Diligence
PMV Pharmaceuticals Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
PMV Pharmaceuticals Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
PMVP Solvency Score
Solvency Due Diligence
PMV Pharmaceuticals Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
PMV Pharmaceuticals Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PMVP Price Targets Summary
PMV Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
PMVP
is 8.925 USD
with a low forecast of 5.05 USD and a high forecast of 18.9 USD.
Ownership
PMVP Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PMVP Price
PMV Pharmaceuticals Inc
| Average Annual Return | -28.29% |
| Standard Deviation of Annual Returns | 51.94% |
| Max Drawdown | -98% |
| Market Capitalization | 92.9m USD |
| Shares Outstanding | 51 440 000 |
| Percentage of Shares Shorted | 5.94% |
Company Profile
PMV Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
PMV Pharmaceuticals, Inc. engages in the development of p53 targeted small molecule drugs for the treatment of cancer. The company is headquartered in Cranbury, New Jersey and currently employs 54 full-time employees. The company went IPO on 2020-09-25. The Company’s lead product candidate, PC14586, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. PC14586 is designed to restore the wild-type conformation by occupying the crevice created by the tyrosine to cysteine mutation in amino acid position 220. The firm is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates, which structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target certain cancers where wild-type p53 function is silenced.
You don't have any saved screeners yet
